Preparing for future pandemics
CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats.
Find out more
Latest News
Latest News
Sinergium paves the way for Latin American mRNA vaccines with new preclinical study
University of Oxford launches world’s first Phase II Nipah virus vaccine trial
Scientists in Korea to create mRNA vaccine against emerging Asian tick-borne virus
Closing in on protection against deadly Nipah virus
Disease outbreak survivors are key to future preparedness
First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial
Korea steps up pandemic response with $18.9m investment in CEPI
A blueprint for access at the heart of outbreak R&D
IAVI’s Lassa fever vaccine shows promise in early clinical trials
Progress towards regionalised vaccine manufacturing remains uneven
Latest News
We want to create a world in which epidemics and pandemics are no longer a threat to humanity.
CEPI is working to galvanise the development of new vaccines and other biologic countermeasures against diseases that could cause the next devastating epidemic or pandemic.
Our approach
Research and development
CEPI is leading a broad range of ambitious programmes that aim to substantially reduce global epidemic and pandemic risk.
Calls for Proposals
Innovators worldwide are invited to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
Process development and manufacturing
CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.
Progress and results
CEPI is catalysing the development of vaccines and biologics against epidemic and pandemic threats, working to make them accessible to everyone who needs them and driving progress on the 100 Days Mission. Learn more about our progress and results.
$12.5 trillion
IMF’s estimate cost of the COVID-19 pandemic to the global economy through 2024
70+
Number of CEPI-supported vaccine candidates or platform technologies.
400+
R&D partners collaborating with CEPI
Emerging infectious diseases affect us all. They do not respect borders.
A commitment to equitable access informs every aspect of our work. It is core to CEPI’s vision of a world in which epidemics and pandemics are no longer a threat to humanity.
CEPI take a systems approach to equitable access, seeking to enable equitable access within a broad ecosystem of national and international public and private sector partners and networks.
We work towards this goal by enabling equitable access directly through financial investments and partnerships, and indirectly through advocacy and policy contributions to the evolving ecosystem.
